New CyPath Lung case study confirming noninvasive diagnostics triggered 51.28% surge.
BioAffinity Technologies released a clinical case study on March 17, 2026, detailing how its CyPath Lung test helped a 71-year-old former smoker with multiple pulmonary nodules avoid invasive procedures. The test returned an “Unlikely Malignancy” result, leading to monitoring via follow-up CT scan that confirmed benign nodules had resolved. This real-world example illustrated the test’s ability to provide actionable results, reduce patient anxiety, support conservative management, and lower healthcare costs by avoiding unnecessary biopsies or bronchoscopies. The positive data reinforced earlier momentum from strong 2025 commercial results—CyPath Lung revenue grew 87% with test volumes up 99%—and the recent launch of a large-scale longitudinal clinical study. High trading volume and retail interest in the small-cap name amplified the move during today’s session, extending gains from prior sessions where the stock had already shown significant volatility on similar news.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.